Clinical Trials
33 trialsNCT05050097 2026-06-05
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03798678 2026-05-27
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07082270 2026-05-15
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT06622005 2026-04-21
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT05675449 2026-04-13
MagnetisMM-20
Pfizer
Phase 1 Active not recruiting
NCT03909412 2026-02-18
CarMob
Hackensack Meridian Health
Phase 1 Recruiting
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05651932 2026-02-10
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc.
Phase 1 Recruiting
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT05137054 2026-01-22
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Regeneron Pharmaceuticals
Phase 1 Recruiting
NCT02199665 2025-11-03
SINE
University of Chicago
Phase 1 Completed
NCT04813653 2025-07-24
Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells
Tel-Aviv Sourasky Medical Center
Phase 1 Completed
NCT02332850 2025-05-01
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Active not recruiting
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT02148913 2024-07-26
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
Corewell Health West
Phase 1 Completed
NCT02101944 2024-05-17
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT03605719 2023-10-06
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT01301807 2023-09-29
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04895410 2023-03-06
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
AbbVie
Phase 1 Terminated
NCT04163107 2022-03-18
MYELOMA-HCQ
Norwegian University of Science and Technology
Phase 1 Completed
NCT02036502 2021-04-08
MK-3475-023
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02095834 2021-01-11
Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02335983 2020-11-06
Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Amgen
Phase 1 Completed
NCT01372540 2019-07-16
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01549431 2019-01-16
Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT01660750 2017-10-18
11-MM-01
Criterium, Inc.
Phase 1 Completed
NCT00603447 2017-05-30
Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Amgen
Phase 1 Completed
NCT01980589 2017-05-30
CHAMPION 2
Amgen
Phase 1 Completed
NCT00150462 2017-05-02
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
Amgen
Phase 1 Completed
NCT01949532 2017-05-02
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Amgen
Phase 1 Completed
NCT01204164 2016-05-06
TG02-101
Tragara Pharmaceuticals, Inc.
Phase 1 Completed
NCT02235740 2016-05-04
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
Novartis
Phase 1 Terminated